CTI BioPharma Corp

NASDAQ:CTIC   9:36:57 AM EDT
2.29
-0.04 (-1.72%)
Products

CTI Biopharma Announces Extension Of FDA Review Period For Pacritinib

Published: 11/30/2021 23:25 GMT
CTI BioPharma Corp (CTIC) - Cti Biopharma Announces Extension of FDA Review Period for Pacritinib in Myelofibrosis With Severe Thrombocytopenia.
Cti Biopharma Corp - Prescription Drug User Fee Act (pdufa) Action Date Has Been Extended by Three Months to February 28, 2022.
Cti Biopharma Corp - FDA Informed Co That It Considers Data Submission to Constitute a "major Amendment" to NDA.
Cti Biopharma Corp - at Current Time, Not Aware of Any Major Deficiencies in NDA for Pacritinib.
Cti Biopharma - in Course of Product Labeling Discussions, FDA Requested Additional Clinical Data, Which Was Submitted to Agency on Nov 24, 2021.